Nicox
 


NicOx is building an international late-stage development and commercial Ophthalmology Company. NicOx is also developing New Molecular Entities through the application of its proprietary nitric oxide-donating R&D platform.

NicOx is headquartered in France and is listed on Euronext Paris.
News / Actus NEWS
16/05/2012 NicOx's Ordinary Shareholder Meeting on May 16, 2012
10/05/2012 NicOx reports first quarter 2012 financial results
04/04/2012 NicOx provides update on U.S. regulatory status of naproxcinod
02/04/2012 NicOx appoints Philippe Masquida EVP, Managing Director of European Operations; Next step in the Company’s strategy to create an international ophthalmology company
21/03/2012 NicOx enters into option agreement to acquire Altacor as a first step towards building an international ophthalmology business
21/03/2012 Jerry St. Peter appointed Executive Vice President and General Manager of NicOx Inc.




Click here for more information




Contact us